Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Interest Income

Income earned on cash, deposits, and investments held by the company.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $5.14M fell 34.9% year over year, behind the -8.0% change in trailing-twelve-month interest income. Sequentially, it rose 14.4% from the prior quarter. Over 3 fiscal years it compounded at +338.2% a year.

Context

  • Interest income amounted to 136.8% of revenue in FY2025.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -34.9% toward the trailing-twelve-month pace of -8.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.14M+14.4% QoQ
Last fiscal yearDec 2025
$20.53M+46.5% YoY
LTMMar 2026
$17.78M-8.0% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.9%——
1 year+46.5%——
3-year CAGR+338.2%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
20.53M USD
Year-over-year change
+46.5%

Interest Income vs competitors

How CNTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.0% is the 6th highest of 10, against a peer median of +6.8%.
  • Over three fiscal years its annual growth of +338.2% compares with a peer median of +85.8%.
CNTA Competitors
Interest Income for CNTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥79.89M CNY+111.1%+101.8%14.3%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$42.53M USD+48.0%—689.7%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$36.88M USD+19.3%+45.5%—
DYNDyne Therapeutics, Inc.LTM Jun 2026$32.68M USD+6.8%+117.1%—
ZLABZai Lab LimitedLTM Jun 2026$27.93M USD-21.5%+31.4%6.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$24.17M USD-30.0%+31.2%3.6%
LEGNLegend Biotech CorporationLTM Sep 2026$23.55M USD-48.6%+69.9%1.7%
CNTACentessa Pharmaceuticals plcLTM Mar 2026$17.78M USD-8.0%+338.2%—
CELCCelcuity Inc.LTM Jun 2026$15.94M USD+45.9%+121.8%—
APGEApogee Therapeutics, Inc.LTM Jun 2026$5.57M USD-83.3%+588.5%—
Peer median (excluding CNTA) —+6.8%+85.8%6.2%

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006.85M015M
Cost of Revenue00000
Gross Profit006.85M015M
Gross Margin——100.0%—100.0%
Research & Development96.32M155.08M124.41M150.24M172.22M
Selling, General & Admin43.01M55.2M53.73M50.81M50.47M
Operating Expenses374.87M212.26M178.14M201.06M222.69M
Depreciation & Amortization34K131K810K942K921K
EBITDA(139.3M)(209.55M)(165.43M)(221.88M)(183.33M)
EBITDA Margin——-2413.9%—-1222.2%
Operating Income(374.87M)(212.26M)(171.28M)(201.06M)(207.69M)
Operating Margin——-2499.4%—-1384.6%
Interest Income0244K10.48M14.02M20.53M
Interest Expense2.55M7.28M9.91M10.09M11.46M
Other Income / Expenses(6.92M)(4.69M)(4.86M)(31.86M)11.98M
Income Before Tax(381.79M)(216.95M)(176.14M)(232.91M)(195.71M)
Pre-Tax Margin——-2570.3%—-1304.8%
Income Tax Expense114K(747K)(25.06M)2.84M1.82M
Net Income(381.9M)(216.21M)(151.09M)(235.76M)(197.53M)
Net Margin——-2204.7%—-1316.9%
EPS (Basic)(4.24)(2.31)(1.57)(2.06)(1.46)
EPS (Diluted)(4.24)(2.31)(1.57)(2.06)(1.46)
Weighted Avg Shares89.99M93.4M96.18M114.47M135.72M
Weighted Avg Shares (Diluted)89.99M93.4M96.18M114.47M135.72M

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.